|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.27 USD | -3.40% |
|
-5.42% | -24.58% |
| Apr. 16 | Omega Therapeutics CFO Joshua Reed to Depart | MT |
| Apr. 16 | Omega Therapeutics, Inc. Announces Executive Changes, Effective as of May 31, 2024 | CI |
Omega Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 97.43 million compared to USD 102.7 million a year ago. Basic loss per share from continuing operations was USD 1.8 compared to USD 2.14 a year ago.
Diluted loss per share from continuing operations was USD 1.8 compared to USD 2.14 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -24.58% | 125M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
OMEGA THERAPEUTICS, INC. 
